title: Impact of conversion from pegylated interferon-α2b to interferon-α2a for treating recurrent hepatitis C after liver transplantation.
authors.forename: Toru
authors.initials: T
authors.lastname: Ikegami
authors.forename: Ken
authors.initials: K
authors.lastname: Shirabe
authors.forename: Tomoharu
authors.initials: T
authors.lastname: Yoshizumi
authors.forename: Norihiro
authors.initials: N
authors.lastname: Furusyo
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Kotoh
authors.forename: Masaki
authors.initials: M
authors.lastname: Kato
authors.forename: Shinji
authors.initials: S
authors.lastname: Shimoda
authors.forename: Yuji
authors.initials: Y
authors.lastname: Soejima
authors.forename: Takashi
authors.initials: T
authors.lastname: Motomura
authors.forename: Takasuke
authors.initials: T
authors.lastname: Fukuhara
authors.forename: Yoshihiko
authors.initials: Y
authors.lastname: Maehara
mesh_terms: D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use; D005260:Female; D006526:Hepatitis C / Q000628:therapy* / Q000821:virology*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000737:chemistry* / Q000627:therapeutic use; D016031:Liver Transplantation / Q000379:methods; D019520:Living Donors; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000737:chemistry / Q000627:therapeutic use; D012008:Recurrence; D012254:Ribavirin / Q000494:pharmacology; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D012254:Ribavirin